Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:KTTA NASDAQ:PULM NASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.02-1.0%$1.33$0.84▼$8.22$3.88M0.1148,600 shs34,697 shsKTTAPasithea Therapeutics$0.78-1.8%$0.77$0.28▼$2.06$19.46M0.22404,809 shs549,445 shsPULMPulmatrix$1.25-1.6%$1.56$1.16▼$9.37$4.57M1.9431,072 shs17,492 shsSBFMSunshine Biopharma$0.28-39.5%$1.01$0.28▼$2.43$1.42M1.37120,788 shs1.45 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%-4.67%+2.00%-37.42%-73.51%KTTAPasithea Therapeutics0.00%-1.91%+5.99%+9.86%-18.33%PULMPulmatrix0.00%-3.63%0.00%-48.56%-79.58%SBFMSunshine Biopharma0.00%-72.94%-71.80%-75.72%-79.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.02-1.0%$1.33$0.84▼$8.22$3.88M0.1148,600 shs34,697 shsKTTAPasithea Therapeutics$0.78-1.8%$0.77$0.28▼$2.06$19.46M0.22404,809 shs549,445 shsPULMPulmatrix$1.25-1.6%$1.56$1.16▼$9.37$4.57M1.9431,072 shs17,492 shsSBFMSunshine Biopharma$0.28-39.5%$1.01$0.28▼$2.43$1.42M1.37120,788 shs1.45 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%-4.67%+2.00%-37.42%-73.51%KTTAPasithea Therapeutics0.00%-1.91%+5.99%+9.86%-18.33%PULMPulmatrix0.00%-3.63%0.00%-48.56%-79.58%SBFMSunshine Biopharma0.00%-72.94%-71.80%-75.72%-79.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 2.00Hold$28.002,645.10% UpsideKTTAPasithea Therapeutics 1.67Reduce$3.00284.57% UpsidePULMPulmatrix 1.00SellN/AN/ASBFMSunshine Biopharma 2.00Hold$7.002,363.92% UpsideCurrent Analyst Ratings BreakdownLatest SBFM, KTTA, PULM, and ALZN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026SBFMSunshine Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026PULMPulmatrix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/APULMPulmatrixN/AN/AN/AN/A$2.45 per shareN/ASBFMSunshine Biopharma$36.31M0.04N/AN/A$4.30 per share0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51M-$2.16N/AN/AN/AN/A-177.52%-140.41%7/28/2026 (Estimated)KTTAPasithea Therapeutics-$20.43M-$3.57N/AN/AN/AN/A-85.48%-77.42%5/21/2026 (Estimated)PULMPulmatrix-$5.16M-$1.23N/AN/AN/AN/A-96.97%-88.53%N/ASBFMSunshine Biopharma-$5.97M-$1.29N/AN/AN/A-18.45%-27.75%-21.57%N/ALatest SBFM, KTTA, PULM, and ALZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AKTTAPasithea Therapeutics-$3.40N/AN/AN/A$0.30 millionN/A5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/15/2026Q1 2026PULMPulmatrixN/A-$0.32N/A-$0.32N/AN/A5/13/2026Q1 2026SBFMSunshine Biopharma-$0.16-$0.25-$0.09-$0.25$9.20 million$8.09 million4/3/2026Q4 2025SBFMSunshine Biopharma-$0.27-$0.46-$0.19-$0.46$10.00 million$8.58 million3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/A3/11/2026Q3 2026ALZNAlzamend Neuro-$0.53-$0.5780-$0.0480-$0.58N/AN/A2/26/2026Q4 2025PULMPulmatrixN/A-$0.25N/A-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A1.991.99KTTAPasithea TherapeuticsN/A11.3511.35PULMPulmatrixN/A12.5512.55SBFMSunshine BiopharmaN/A4.222.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%KTTAPasithea Therapeutics23.92%PULMPulmatrix11.84%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro1.39%KTTAPasithea Therapeutics2.00%PULMPulmatrix0.62%SBFMSunshine Biopharma0.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro43.80 million3.75 millionNo DataKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionablePULMPulmatrix203.65 million3.63 millionNot OptionableSBFMSunshine Biopharma35.01 million5.00 millionNot OptionableSBFM, KTTA, PULM, and ALZN HeadlinesRecent News About These CompaniesSBFM Share News TodayMay 15 at 4:29 AM | uk.investing.comTarsus Pharmaceuticals (NASDAQ:TARS) and Sunshine Biopharma (NASDAQ:SBFM) Critical SurveyMay 8, 2026 | americanbankingnews.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearApril 6, 2026 | accessnewswire.comASunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)October 28, 2025 | accessnewswire.comASunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSunshine Biopharma stock rises after Health Canada approval for DomperidoneOctober 28, 2025 | za.investing.comSunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | finanznachrichten.deSunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 21, 2025 | finanznachrichten.deSunshine Biopharma announces commercial launch of doxycycline in CanadaOctober 20, 2025 | msn.comSunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 20, 2025 | accessnewswire.comASunshine Biopharma stock soars after launch of cholesterol drug PravastatinOctober 16, 2025 | au.investing.comSunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian UnitOctober 16, 2025 | msn.comSunshine Biopharma Launches Cholesterol Fighting Medicine PravastatinOctober 16, 2025 | accessnewswire.comASunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level ExecutionOctober 14, 2025 | finanznachrichten.deSunshine Biopharma allocates $5M for investment in bitcoinOctober 14, 2025 | msn.comSunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)October 14, 2025 | accessnewswire.comASunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)October 14, 2025 | accessnewswire.comASunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury ResilienceOctober 14, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBFM, KTTA, PULM, and ALZN Company DescriptionsAlzamend Neuro NASDAQ:ALZN$1.02 -0.01 (-0.97%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.69%) As of 05/15/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Pasithea Therapeutics NASDAQ:KTTA$0.78 -0.01 (-1.78%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.76 -0.02 (-2.45%) As of 05/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Pulmatrix NASDAQ:PULM$1.25 -0.02 (-1.50%) As of 05/15/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Sunshine Biopharma NASDAQ:SBFM$0.28 -0.19 (-39.46%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.30 +0.02 (+7.00%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
